Author

Ayurzana Purevdorj

Observed name: A. Purevdorj

Observed institutions: Klinik Hietzing, IRCCS Ospedale San Raffaele

ORCID: 0009-0002-2071-381X

Observed ORCID: 0009-0002-2071-381X

OpenAlex ID: A5116149270

Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells

2018 · Margherita Norelli, Barbara Camisa, et al. · Nature Medicine · 1,448

Durvalumab Prolongs Overall Survival, Whereas Radiation Dose Escalation > 66 Gy Might Improve Long-Term Local Control in Unresectable NSCLC Stage III: Updated Analysis of the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLSTAR)

2025 · Franz Zehentmayr, Petra Feurstein, et al. · Cancers · 8

Immunotherapy Improves Clinical Outcome in Kirsten Rat Sarcoma Virus-Mutated Patients with Unresectable Non-Small Cell Lung Cancer Stage III: A Subcohort Analysis of the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLSTAR)

2025 · Elvis Ruznic, Marisa Klebermass, et al. · Journal of Clinical Medicine · 4

194P: Durvalumab prolongs overall survival whereas radiation dose escalation >66 Gy improves long-term local control in unresectable NSCLC stage III: Updated analysis of the Austrian radio-oncological lung cancer study association registry (ALLSTAR)

2025 · F. Zehentmayr, P. Feurstein, et al. · Journal of Thoracic Oncology · 1

916 Blood biomarkers in NSCLC stage III: results from the Austrian radio-oncologicaL Lung cancer STudy Association Registry (ALLSTAR)

2026 · Alexandra Hochreiter, Markus Stana, et al. · Radiotherapy and Oncology

699 Durvalumab improves progression-free survival and sequential radiotherapy improves locoregional and local control in elderly NSCLC Stage III patients

2026 · Brane Grambozov, Josef Karner, et al. · Radiotherapy and Oncology

MLR and dMLR Predict Locoregional Control and Progression-Free Survival in Unresectable NSCLC Stage III Patients: Results from the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLSTAR)

2025 · Alexandra Hochreiter, Markus Stana, et al. · Journal of Clinical Medicine

Durvalumab Is Associated with Prolonged Progression-Free Survival, While Concomitant Chemoradiotherapy May Improve Both Locoregional and Local Control in Elderly Patients with Unresectable NSCLC Stage III: Subanalysis of the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLSTAR)

2025 · Franz Zehentmayr, Josef Karner, et al. · Medical Sciences

2579 HDR brachytherapy as monotherapy in the treatment of high-risk prostate cancer

2025 · Oxana Komina, Bettina Kohl, et al. · Radiotherapy and Oncology

203P: Immunotherapy improves clinical outcome in KRAS mutated patients with unresectable NSCLC stage III: A subcohort analysis of the Austrian radio-oncological lung cancer study association regristry (ALLSTAR)

2025 · F. Zehentmayr, M. Klebermass, et al. · Journal of Thoracic Oncology

Works count: 10

Citation count: 1,461

H-index: 3

I10-index: 1